Ask AI
ProCE Banner Activity

CaDAnCe-101 Update: Phase I Study Evaluating BTK Degrader BGB-16673 in R/R CLL/SLL

Conference Coverage
Slideset

In this updated analysis from a phase I trial, the BTK protein degrader BGB-16673 was well tolerated in patients with heavily pretreated R/R CLL/SLL and demonstrated antitumor activity, including in patients with BTK mutations and those previously treated with covalent and noncovalent BTK inhibitors and BCL2 inhibitors. 

Released: December 11, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education in partnership with Smart Patients

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.

AstraZeneca

BeOne Medicines

Genentech

Geron Corporation

Incyte

Johnson & Johnson

Lilly

Novartis Pharmaceuticals Corporation

Partners

Smart Patients

ProCE Banner

Target Audience

This activity is intended for healthcare professionals who care for patients with malignant or nonmalignant hematologic disorders.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply recently presented data to clinical practice to expand treatment options and enhance outcomes for patients with malignant or nonmalignant hematologic disorders

  • Evaluate new data on novel agents and therapeutic approaches for patients with malignant or nonmalignant hematologic disorders

  • Appraise how new trial findings might advance the treatment of patients with malignant or nonmalignant hematologic disorders in the future

  • Support informed shared decision-making for patients with malignant and nonmalignant hematologic disorders through accessible discussion of the potential clinical implications of recently presented data